Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine
Open Access
- 29 June 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (6) , e40342
Abstract
Bendamustine (BDM) is an active chemotherapeutic agent approved in the U. S. for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma. Its chemical structure suggests it may have alkylator and anti-metabolite activities; however the precise mechanism of action is not well understood. Here we report the concentration-dependent effects of BDM on cell cycle, DNA damage, checkpoint response and cell death in HeLa cells. Low concentrations of BDM transiently arrested cells in G2, while a 4-fold higher concentration arrested cells in S phase. DNA damage at 50, but not 200 µM, was efficiently repaired after 48 h treatment, suggesting a difference in DNA repair efficiency at the two concentrations. Indeed, perturbing base-excision repair sensitized cells to lower concentrations of BDM. Timelapse studies of the checkpoint response to BDM showed that inhibiting Chk1 caused both the S- and G2-arrested cells to prematurely enter mitosis. However, whereas the cells arrested in G2 (low dose BDM) entered mitosis, segregated their chromosomes and divided normally, the S-phase arrested cells (high dose BDM) exhibited a highly aberrant mitosis, whereby EM images showed highly fragmented chromosomes. The vast majority of these cells died without ever exiting mitosis. Inhibiting the Chk1-dependent DNA damage checkpoint accelerated the time of killing by BDM. Our studies suggest that BDM may affect different biological processes depending on drug concentration. Sensitizing cells to killing by BDM can be achieved by inhibiting base-excision repair or disrupting the DNA damage checkpoint pathway.Keywords
This publication has 23 references indexed in Scilit:
- Thymine DNA Glycosylase Is Essential for Active DNA Demethylation by Linked Deamination-Base Excision RepairCell, 2011
- Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensationMolecular Cytogenetics, 2010
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphomaCancer Science, 2010
- Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphomaCancer Chemotherapy and Pharmacology, 2010
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating AgentsClinical Cancer Research, 2008
- Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathwaysJournal of Cancer Research and Clinical Oncology, 2007
- The enigmatic thymine DNA glycosylaseDNA Repair, 2007
- In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemiaLeukemia, 2002
- Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell linesJournal of Cancer Research and Clinical Oncology, 2002
- Functional interactions and signaling properties of mammalian DNA mismatch repair proteinsCell Death & Differentiation, 2001